MetaVia Announces Update on Obesity and Metabolic Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MTVA?
Source: PRnewswire
- Conference Schedule: MetaVia Inc. will present an update on its novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026, at 10:15 AM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the latest advancements in cardiometabolic disease treatments.
- DA-1726 Development Progress: The company’s DA-1726, a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, demonstrated best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose trial, potentially outperforming selective GLP1R agonists.
- Clinical Effects of Vanoglipel: Vanoglipel, a novel GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in pre-clinical studies, effectively reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control.
- Future Outlook: The promising results of MetaVia's new therapies in clinical trials position the company strategically for significant market opportunities in the treatment of cardiometabolic diseases, potentially enhancing its competitive edge in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.540
Low
40.00
Averages
47.50
High
55.00
Current: 1.540
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia Announces Update on Obesity and Metabolic Therapies
- Conference Schedule: MetaVia Inc. will present an update on its novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026, at 10:15 AM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the latest advancements in cardiometabolic disease treatments.
- DA-1726 Development Progress: The company’s DA-1726, a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, demonstrated best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose trial, potentially outperforming selective GLP1R agonists.
- Clinical Effects of Vanoglipel: Vanoglipel, a novel GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in pre-clinical studies, effectively reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control.
- Future Outlook: The promising results of MetaVia's new therapies in clinical trials position the company strategically for significant market opportunities in the treatment of cardiometabolic diseases, potentially enhancing its competitive edge in the biotechnology sector.
See More
MetaVia Announces Strong Global IP Portfolio Supporting DA-1726
- Intellectual Property Protection: MetaVia Inc. announced that its lead asset DA-1726 has secured 39 granted and pending patents in the U.S. and internationally, with patent protection extending to 2041, providing a solid foundation for the company's long-term strategy.
- Clinical Data Highlights: Recent clinical data revealed a promising 9% weight loss at the 48 mg dose of DA-1726, alongside significant improvements in waist size and blood sugar levels, indicating its potential in treating obesity and related metabolic disorders.
- Market Performance Analysis: Despite a staggering 90.85% decline in stock price over the past 12 months, the current RSI of 23.34 suggests the stock may be undervalued with rebound potential, trading at $1.84 near its 52-week low of $1.61.
- Analyst Rating Upgrade: HC Wainwright & Co. upgraded MetaVia's stock rating to 'Buy' with a target price raised to $40.00, reflecting confidence in its future growth potential, even as the overall healthcare sector shows lackluster performance.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Advantage: MetaVia Inc. currently holds 39 granted and pending patents covering both U.S. and international markets, providing protection until 2041, thereby ensuring the market competitiveness and commercialization potential of its core asset DA-1726.
- DA-1726 Clinical Data Highlights: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, waist circumference reduction, and improvements in blood sugar levels, indicating its best-in-class potential in treating obesity and metabolic diseases, further solidifying the company's position in the rapidly growing biotech sector.
- Clinical Trial Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in DA-1726's tolerability and its potential advantages over existing GLP-1 treatments.
- Market Outlook: The patent protection and clinical data support MetaVia's long-term strategic development in the obesity and metabolic disease treatment space, which is expected to generate substantial market value and investment returns for the company.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Strength: MetaVia Inc. currently holds 39 granted and pending patents across the U.S. and internationally, providing protection until 2041, ensuring the uniqueness and competitive edge of its core asset DA-1726 in the treatment of obesity and related metabolic disorders.
- Promising Clinical Data: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, notable waist circumference reduction, and improved blood sugar levels, all with a favorable safety profile, highlighting its potential as a leading obesity treatment and reinforcing MetaVia's market position.
- Future Research Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in the therapy's tolerability and its potential advantages over existing GLP-1 treatments.
- Strategic Development Focus: The intellectual property protection aligns with MetaVia's long-term strategy in the obesity and metabolic disease sectors, aiming to meet the growing market demand through innovative therapies and drive the company's future commercialization efforts.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Size: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which includes 3,005,574 shares of common stock and 4,508,361 Series C and D warrants, with proceeds aimed at advancing the clinical development of obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Warrant Details: The Series C and D warrants were issued at a price of $3.10 per share, are immediately exercisable, with Series C warrants valid for five years and Series D for two years, potentially yielding up to $28 million in future proceeds if fully exercised, enhancing the company's financial flexibility.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, ensuring a smooth fundraising process and reflecting market confidence in MetaVia's future growth prospects.
- Clinical Trial Outlook: MetaVia is conducting a Phase 1b clinical trial for DA-1726, and positive data could trigger the call option for Series D warrants, further enhancing the company's competitive position in the obesity treatment market.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Amount: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which will be directed towards the clinical development of its obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Shares and Warrants: The offering included 3,005,574 shares of common stock and 4,508,361 Series C and D warrants priced at $3.10 per share, indicating market confidence in its products and future potential.
- Future Revenue Potential: If the warrants are fully exercised, MetaVia could yield up to $28 million in future gross proceeds, providing substantial financial support for its research and operational needs.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for this offering, showcasing its expertise and influence in the biotechnology financing sector.
See More
MetaVia Announces Update on Obesity and Metabolic Therapies
- Conference Schedule: MetaVia Inc. will present an update on its novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026, at 10:15 AM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the latest advancements in cardiometabolic disease treatments.
- DA-1726 Development Progress: The company’s DA-1726, a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, demonstrated best-in-class potential for weight loss, glucose control, and waist reduction in a Phase 1 multiple ascending dose trial, potentially outperforming selective GLP1R agonists.
- Clinical Effects of Vanoglipel: Vanoglipel, a novel GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in pre-clinical studies, effectively reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control.
- Future Outlook: The promising results of MetaVia's new therapies in clinical trials position the company strategically for significant market opportunities in the treatment of cardiometabolic diseases, potentially enhancing its competitive edge in the biotechnology sector.
See More
MetaVia Announces Strong Global IP Portfolio Supporting DA-1726
- Intellectual Property Protection: MetaVia Inc. announced that its lead asset DA-1726 has secured 39 granted and pending patents in the U.S. and internationally, with patent protection extending to 2041, providing a solid foundation for the company's long-term strategy.
- Clinical Data Highlights: Recent clinical data revealed a promising 9% weight loss at the 48 mg dose of DA-1726, alongside significant improvements in waist size and blood sugar levels, indicating its potential in treating obesity and related metabolic disorders.
- Market Performance Analysis: Despite a staggering 90.85% decline in stock price over the past 12 months, the current RSI of 23.34 suggests the stock may be undervalued with rebound potential, trading at $1.84 near its 52-week low of $1.61.
- Analyst Rating Upgrade: HC Wainwright & Co. upgraded MetaVia's stock rating to 'Buy' with a target price raised to $40.00, reflecting confidence in its future growth potential, even as the overall healthcare sector shows lackluster performance.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Advantage: MetaVia Inc. currently holds 39 granted and pending patents covering both U.S. and international markets, providing protection until 2041, thereby ensuring the market competitiveness and commercialization potential of its core asset DA-1726.
- DA-1726 Clinical Data Highlights: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, waist circumference reduction, and improvements in blood sugar levels, indicating its best-in-class potential in treating obesity and metabolic diseases, further solidifying the company's position in the rapidly growing biotech sector.
- Clinical Trial Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in DA-1726's tolerability and its potential advantages over existing GLP-1 treatments.
- Market Outlook: The patent protection and clinical data support MetaVia's long-term strategic development in the obesity and metabolic disease treatment space, which is expected to generate substantial market value and investment returns for the company.
See More
MetaVia Unveils Robust Intellectual Property Portfolio
- Intellectual Property Strength: MetaVia Inc. currently holds 39 granted and pending patents across the U.S. and internationally, providing protection until 2041, ensuring the uniqueness and competitive edge of its core asset DA-1726 in the treatment of obesity and related metabolic disorders.
- Promising Clinical Data: At the 48 mg dose, DA-1726 demonstrated a significant weight loss of approximately 9%, notable waist circumference reduction, and improved blood sugar levels, all with a favorable safety profile, highlighting its potential as a leading obesity treatment and reinforcing MetaVia's market position.
- Future Research Plans: MetaVia plans to conduct 16-week titration studies targeting doses of 48 mg and 64 mg, with results expected in Q4 2026, reflecting the company's confidence in the therapy's tolerability and its potential advantages over existing GLP-1 treatments.
- Strategic Development Focus: The intellectual property protection aligns with MetaVia's long-term strategy in the obesity and metabolic disease sectors, aiming to meet the growing market demand through innovative therapies and drive the company's future commercialization efforts.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Size: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which includes 3,005,574 shares of common stock and 4,508,361 Series C and D warrants, with proceeds aimed at advancing the clinical development of obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Warrant Details: The Series C and D warrants were issued at a price of $3.10 per share, are immediately exercisable, with Series C warrants valid for five years and Series D for two years, potentially yielding up to $28 million in future proceeds if fully exercised, enhancing the company's financial flexibility.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, ensuring a smooth fundraising process and reflecting market confidence in MetaVia's future growth prospects.
- Clinical Trial Outlook: MetaVia is conducting a Phase 1b clinical trial for DA-1726, and positive data could trigger the call option for Series D warrants, further enhancing the company's competitive position in the obesity treatment market.
See More
MetaVia Inc. Closes $9.3 Million Public Offering to Advance Obesity Treatment Development
- Funding Amount: MetaVia Inc. has successfully closed a public offering raising approximately $9.3 million, which will be directed towards the clinical development of its obesity treatment drug DA-1726, demonstrating the company's ongoing commitment to cardiometabolic diseases.
- Shares and Warrants: The offering included 3,005,574 shares of common stock and 4,508,361 Series C and D warrants priced at $3.10 per share, indicating market confidence in its products and future potential.
- Future Revenue Potential: If the warrants are fully exercised, MetaVia could yield up to $28 million in future gross proceeds, providing substantial financial support for its research and operational needs.
- Underwriter Role: Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for this offering, showcasing its expertise and influence in the biotechnology financing sector.
See More
